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Introduction
Colon cancer is the third most common type of cancer 
worldwide and a leading cause of cancer death. As per 
the American Cancer Society, there will be an estimated 
145,600 new cases of colon cancer and 51,020 will die 
from colon cancer in 2019 (American Cancer Society, 
2019). The evolution of colon cancer seems to follow a 
predictable pattern of histologic changes and concurrent 
genetic and epigenetic changes, which ultimately provide 
a growth advantage resulting in the clonal expansion 
of transformed cells (Schlussel et al., 2014). At least 
three forms of genomic instability contribute to colon 
cancer, including microsatellite instability, chromosome 
instability, and chromosomal translocations (Grady, 
2004). A complex cellular community exists within a 
malignant tumor. This community was constituted by 
oncogenically transformed cells, non-neoplastic cells 
such as stromal and immune cells, and microbes such 
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as bacteria and viruses in some cases (Kostic et al., 
2012). This cellular heterogeneity is highly complex to 
understand and treat accordingly. Surgical resection and 
chemotherapy elicit significant side effects and toxicities 
which affects patient’s quality of life and survival. The 
toxicities such as hair loss, nausea, vomiting etc., drug 
resistance and inter-individual differences in response to 
any treatment are major limitations associated with current 
chemotherapeutic drugs (Pullarkat et al., 2001). 
In a healthy gut, the normal bacterial flora maintains 
homeostasis with the host (Ley et al., 2006). However, 
changes in bacterial populations and their metabolic 
products have been linked to several diseases including 
ulcerative colitis, crohn’s disease and colon cancer (Kaur 
et al., 2011; Marchesi et al., 2011; Sasaki and Klapproth, 
2012). Studies suggest that the presence of certain bacteria 
may contribute to both the induction of inflammation in 
inflammatory bowel disease (IBD) and the progression 
of inflammation to neoplasia (Erdman et al., 2003a; Chu 
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et al., 2004; Maggio-Price et al., 2005). Helicobacter 
organisms have been linked to IBD (Burich et al., 2001; 
Jiang et al., 2002), as well as liver cancer (Sipowicz et al., 
1997), colon cancer in mice (Engle et al., 2002; Erdman 
et al., 2003a; Erdman et al., 2003b), and gastric cancers 
in humans (Uemura et al., 2002). It is evaluated that 
there are 1014 cell number of bacterial species present 
in human gastrointestinal tract, which is more than 10-
fold the number of eukaryotic human cells (Ley et al. 
2006) and perhaps as many as 10-fold more viruses. 
Natural products have been used worldwide as traditional 
medicines for thousands of years to treat various forms of 
diseases including cancer. Several studies have revealed 
that natural products exhibit an extensive spectrum of 
biological activities such as, stimulation of the immune 
system, antibacterial, antiviral, anti-hepatotoxic, anti-
ulcer, anti-inflammatory, antioxidant, anti-mutagenic, 
and anti-cancer effects (Miyata, 2007; Espin et al., 2007). 
Pyrogallol is a natural product, a catechin type compound 
approved by Food and Drug Administration (FDA) as 
colour additive. Pyrogallol is used in the manufacturing 
of pharmaceuticals and pesticides and has been used for 
medicinal purposes as a topical antipsoriatic medicine 
(Willsteed and Regan, 1985). Pyrogallol reported as an 
anti-lung cancer agent by arresting cell cycle at G2-M 
phase in lung cancer cells and reduces lung tumor in animal 
model (Han et al., 2008; Yang et al., 2009). Furthermore, 
pyrogallol was shown to be an effective compound against 
gastric cancer in vitro (Park et al., 2008). Our previous 
study showed that pyrogallol isolated from Acacia 
nilotica can restrict colon cancer cell proliferation (in 
vitro) by modulating the cell cycle, inducing apoptosis 
and genotoxicity (Revathi et al., 2018). However in vitro 
model has numerous limitations such as the lack of tumour 
cellular network and their associated signaling. To check 
the efficacy of anti-colon cancer effect of pyrogallol in vivo 
studies are warranted. In vivo studies in animal models 
have been viewed as critical tools necessary to study the 
molecular mechanisms of colorectal carcinogenesis, to 
test potential preventative and therapeutic strategies, and 
to translate hypotheses derived from cell models into the 
complex physiology of the colon (Johnson and Fleet, 
2013). As per the above statement to delineate the role of 
pyrogallol on colon cancer in this study we induced colon 
cancer by inoculating H. pylori in mice and evaluated the 
anti-tumour efficacy of pyrogallol. Furthermore, in vivo 
pre clinical toxicity of pyrogallol was assessed including 
checking the histology of major tissues, body weight and 
complete blood count and blood biochemical parameters.
Materials and Methods 
Plant material
The fresh leaves of A. nilotica were collected from the 
Foundation for Revitalization of Local Health Traditions, 
Bangalore, India (Latitude 12.9715987; Longitude 
77.5945627). The plant was taxonomically identified by 
botanist and deposited in herbarium of Periyar University. 
Preparation of A. nilotica extract (ACE)
Extraction was carried out as described earlier (Revathi 
et al., 2017). Briefly, fresh leaves of A. nilotica was 
collected and washed in tap water. It was shade dried for 10 
days and made into a fine powder of 40 mesh in size using 
the laboratory mill. 100 gm of powder was filled in a clean 
flat-bottomed glass container and soaked in 70% acetone 
for 72 h. The container with its content was sealed and 
kept for a period of three days accompanying occasional 
shaking and stirring. Extract was filtered using whatman 
no. 1 filter paper and it was dried at room temperature.
Isolation and characterization of pyrogallol
ACE was fractionated by column chromatography 
using different proportion of ethyl acetate and hexane 
and fractions were subjected to HPLC and pyrogallol 
was isolated based on retention time and absorbance of 
reference standard pyrogallol (Sigma Aldrich, Louis MO, 
USA). Further structure of pyrogallol was elucidated by 
spectral analysis such as FTIR, 1H NMR, 13CNMR, 
GCMS, LCMS and XRD.
Evaluation of in vivo toxicity
In vivo acute toxicity was evaluated according to 
the OECD guidelines (OECD, 2001). Healthy young, 
non-pregnant, nulliparous Swiss albino mice, weighting 
about 25-28 gm (8 weeks old) were placed in clean 
polypropylene cages with access to food and water. 
These cages were maintained in an air-conditioned 
animal house at 26 ± 2°C, 65–80% relative humidity and 
12 h light-dark cycle. The animals were provided with 
commercial mice pellet diet and deionized water. After 
one week acclimation, the mice were randomly divided 
into 7 groups, each group consisted of five female and five 
male mice. They were kept separately in polypropylene 
cages. Group I served as control and received normal 
saline intraperitoneally. Group II, III, and IV treated 
with ACE at 10, 20, and 40 mg/kg of body weight (i.p) 
respectively, every 2 days for the period 21 days. Group V, 
VI, and VII mice were injected with pyrogallol at 10, 20, 
and 40 mg/kg of body weight (i.p) respectively, every 2 
days for the period 21 days. At the end of the experimental 
period the major organs (heart, liver, kidney and lungs) 
were excised and fixed in 4% para formaldehyde solution 
and made into 200 µm sections which were stained with 
hematoxylin and eosin (H and E) and observed under a 
microscope at 20X for tissue damage. Blood sample were 
collected and subjected to evaluation of blood cell count 
and biochemical parameters. All the experiments were 
conducted under the guidelines of Institutional Animal 
Ethical Committee.
Blood biochemical parameters
Serum was obtained by centrifugation of whole blood 
at 3,000 rpm for 15 min. Serum levels of creatinine, 
alkaline phosphatase (ALP), total protein (TP), total 
cholesterol; tri-glyceride (TG), uric acid, blood urea 
nitrogen (BUN), glutamic oxaloacetic acid (SGOT), 
glutamic pyruvic transaminase (SGPT) were examined. 
0.1 ml of 15 gl-1 EDTA-Na was pre-added into 1 ml of 
blood samples and blood samples were immediately used 
for testing within 2 h. The blood counts, including total 
count of red blood cells, white blood cell (neutrophils, 
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Pre clinical toxicity analysis of ACE and pyrogallol
ACE and pyrogallol at the different dose of 10, 
20 mg and 40 mg/kg body weight were administered 
intraperitoneally. Results revealed that no treatment 
related toxic symptom or mortality was observed. In 
addition there was no adverse effect on the behavioral 
responses of the tested mice at all doses examined. 
Physical observations indicated no signs of changes in 
the skin, fur, eyes mucous membrane, behavior patterns, 
tremors, salivation, and diarrhea of the mice. Further 
examination showed that there was no significant change 
in the hematological and biochemical parameters in 
the ACE and pyrogallol treated group as compared to 
the normal control group (Table 1). Mice treated with 
pyrogallol (40mg/kg of body weight) showed significant 
decrease in the level of hemoglobin (p<0.05), RBC count 
(p<0.05). The level of BUN (p<0.05) and SGOT (p<0.05) 
was significantly increased in mice treated with pyrogallol 
at 40mg/kg of body weight (Table 1). Hematoxylin and 
eosin staining of major organs (heart, kidney, liver, and 
lungs) revealed no significant differences in ACE and 
pyrogallol treated mice compared to control (Figure 1A 
and B). Liver showed normal hepatic lobular architecture, 
intact central vein with trapped red blood cells in a liver 
section from ACE and pyrogallol treated animals. The 
kidney revealed normal glomeruli, proximal and distal 
tubules, interstitium, and blood vessels. The lung tissue 
showed normal alveoli and heart muscle showed normal 
morphology compared to control (Figure 1A and B). No 
abnormal gross findings were observed in the necropsies 
of any of the mice. The food and water consumptions of 
the treated mice, which were measured throughout the 
study, were also not significantly different compared to 
the control mice (data not shown). 
lymphocytes, monocytes, eosinophils, basophils), and 
blood platelets were analyzed. 
H. pylori infection of xenografts in nude mice
C57BL/6 mice infected with Helicobacter pylori 
were generously donated by the Department of 
Gastroenterology, Microbiology and Pathology, Chennai 
Medical College Hospital and Research Centre (SRM 
Group), Tiruchirapalli, India (Affiliated to the Tamil Nadu 
Dr. M. G. R. Medical University, Chennai). Animals were 
in the range of 9 weeks to 10-month-old including both 
male and female. The anti-tumour e-ciency of pyrogallol 
and ACE were assessed in tumor-induced mice. When the 
volume of the xenograft tumour reached approximately 
40-60 mm3 the mice were randomly divided into 4 
groups. Group I: Mice treated with PBS as control, Group 
II: Mice treated with 40 mg/kg body weight of ACE, 
Group III: Mice treated with 40 mg/kg body weight of 
pyrogallol, Group IV: Mice treated with 10 mg/kg body 
weight of Doxorubicin. All compounds and vehicle were 
administered intravenously every 2 days, and all mice 
were then observed for 21 days. The tumour diameters and 
body weight were measured every 3 days. Doxorubicin 
was used as positive control. All the experiments were 
conducted under the guidelines of Institutional Animal 
Ethical Committee.
Statistical Analysis
The data were expressed as mean ± standard deviation 
(n=6). The statistical software SPSS version 17.0 was 
used for the analysis. Analysis of variance was done to 
find p values. P<0.01or 0.05 was considered significant 
compare to control.
Results 
Parameter Control ACE (mg/kg body weight) Pyrogallol (mg/kg body weight)
10 20 40 10 20 40
Hemoglobin (g/dL) 13.22±0.5 13.6±0.1 13.43±0.1 13.3±0.1 13.0±0.05 12.8±0.2* 12.4±0.0*
RBC (million/mm3) 5.1±0.1 5.05±0.1 5.01±0.3 4.96±0.5 4.9±0.5 4.86±0.6* 4.61±0.6*
WBC (T/mm3) 4.03±0.6 4.0±0.1 3.9±0.2 3.8±0.2 4.1±0.3 3.98±0.2 3.97±0.2
Neutrophils 35±0.6 35±0.2 35±0.2 35±0.1 35±0.1 35±0.1 35±0.2
Monocytes 3.5±0.1 3.5±0.1 3.5±0.1 3.5±0.5 3.5±0.5 3.5±0.2 3.5±0.1
Lymphocytes 55±0.3 55±0.1 55±0.4 55±0.1 55±0.8 55±0.7 55±0.8
Eosinophils 0.2±0.3 0.2±0.1 0.2±0.4 0.2±0.7 0.2±0.1 0.2±0.6 0.2±0.6
Basophils 0±0.05 0±0.05 0±0.05 0±0.05 0±0.05 0±0.05 0±0.05
Platelets (lakh/mm3) 1.63±0.3 1.63±0.6 1.69±0.2 1.71±0.1 1.74±0.5 1.75±0.5 1.77±0.5*
Cholesterol (mg/dL) 110 ±0.1 111 ±0.5 111 ±0.3 112 ±0.4 108 ±0.5 105 ±0.1 102 ±0.5
Uric Acid (mg/dL) 6.3±0.3 6.5±0.1 6.4±0.8 6.6±0.7 6.0±0.1 6.2±0.3 6.5±0.3
Alkaline Phosphatase (IU/L) 63±0.0 63±0.5 62.8±0.0 61.8±0.6 63.8±0.5 63.5±0.1 62.1±0.5
Total Protein (gm/dL) 6.3±0. 3 6.28±0. 1 6.23±0. 3 6.19±0. 5 6.3±0. 0 6.22±0. 3 6.27±0. 3
Triglyceride (mg/dL) 55±0.7 59±0.5 59±0.8 60±0.1 62±0.5 63±0.7* 65±0.1*
BUN (mg/dL) 12.6±0.0 12.4±0.6 12.3±0.1 12.2±0.5 12.9±0.1 13.2±0.5 13.7±0.8*
SGOT (IU/L) 16.3±0.5 16.1±0.4 16.2±0.2 16.0±0.5 16.9±0.5 17.3±0.2 19.3±0.0*
SGPT (IU/L) 10.6±  0.6 10.9± 0.1 11.2± 0.5 11.6± 0.5 10.6± 0.6 10.1± 0.0 10.0± 0.5
Table 1. Toxicity Associated Biochemical Parameters of Mice Treated with ACE and Pyrogallol Values are Expressed 
as mean ± SD (n=4 for each group). * indicates significant difference at p<0.05 compare to control
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Anti-tumour effect of  ACE and pyrogallol in 
H. pylori-induced colon cancer nude mice model
Anti-tumour effect of ACE and pyrogallol was 
compared with doxorubicin using H. pylori induced colon 
cancer model. Interestingly, administration of pyrogallol 
at 40 mg/kg of body weight significantly reduced the 
tumour size about 96% in a time-dependent manner 
similar to that of doxorubicin (Figure 2). Whereas, in ACE 
treated mice tumour continued to grow similar to that in 
control group. There was mild change in the body weight 
observed in ACE and pyrogallol treated mice, however, 
it is better than doxorubicin treated mice (Figure 3). The 
results clearly suggest that ACE and pyrogallol treatment 
were better tolerated by in vivo system. Noticeably our 
data states that pyrogallol is an effective anti colon tumour 
agent with less toxicity in comparison with doxorubicin.
Discussion 
Cancer is the most deadly disease and its incidence rate 
enhanced every year. Unfortunately currently available 
chemotherapy drugs elicit intolerable toxicities which 
impacts on patient’s quality of life and survival (Mc 
Cleary et al., 2013). Surgical resection is promising 
treatment option for colon cancer treatment however; post 
surgical clinical consequences are remain unresolved. 
World health organization (WHO) emphasis the 
importance of practicing natural medicines to treat 
different life threatening ailments including cancer 
(Cheuka et al., 2017). Plant derived products such as 
vincristine, vinblastine, taxol etc. have contributed 
significantly in treating different types of tumours 
(Demain and Vaishnav, 2011). However, drug resistance 
and recurrence of cancer always are alarming factors 
and would necessitate discovery of new drugs which can 
overcome post treatment clinical complications with a 
better quality of life for patients.
Figure 1. Histopathological Analysis of Heart, Kidney, Liver and Lung of the Mice Mice were Treated with Different 
Concentration of ACE (A) and Pyrogallol (B). 200 μm sections of heart, kidney, liver and lung were stained with 
H&E after treatment period. The images were photographed at 20X. No adverse side effects/changes were observed. 
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In this study, we explored the anti-cancer activity of 
acetone extract of Acacia nilotica (ACE) and its active 
component, pyrogallol. Recently we isolated pyrogallol 
from ACE and studied the in vitro anti colon cancer 
activity. In comparison with ACE, pyrogallol showed 
profound in vitro anti-cancer activity against HT-29 cells 
by sparing normal colon cells (CRL-1831) (Revathi et al., 
2018). Further we reported that pyrogallol is a genotoxic 
agent and induced apoptosis in colon cancer cells by 
modulating cell cycle progression and inhibition of 
migration in HT-29 cells (Revathi et al., 2018). However 
these in vitro evidences are not enough to reach concrete 
conclusions because in vitro models do not mimic the in 
vivo system. Tumour development and progression in in 
vivo is entirely different scenario since tumour cellular 
network is highly complex and achieving reproducibility in 
in vivo system based on in vitro data is not guaranteed. It is 
well known that in vivo studies in animal models have been 
viewed as critical tools necessary to study the therapeutic 
strategies, to test potential compounds and investigate 
molecular mechanisms of colon carcinogenesis. This will 
enable to translate hypotheses derived from cell models 
into the complex physiology of the colon (Johnson and 
Fleet, 2013). 
In this study, we developed in vivo colon tumour model 
by inoculating Helicobacter pylori in to mice as described 
earlier. To determine the effective and tolerance dose of 
ACE and pyrogallol for in vivo anti tumour experiment, 
we treated the mice with different concentrations of ACE 
and pyrogallol (10, 20 and 40 mg/kg body weight) every 
2 days and observed for changes in behaviours, mortality 
and histology of vital organs (heart, kidney, liver, lungs) 
for damage (Figure 1). Further, blood cell counts and the 
blood biochemical parameters were analyzed in ACE and 
pyrogallol treated mice. Both total blood cell RBC, WBC’s 
(neutrophils, monocytes, lymphocytes, eosinophils, 
basophils) and platelets counts and levels of biochemical 
parameters (cholesterol, uric acid, alkaline phosphatase, 
total protein, triglyceride, urea nitrogen, SGOT, and 
SGPT) did not changed significantly following ACE and 
Figure 2. Graphical Representation of Tumor Inhibition in Mice in a Time Dependent Manner. Tumor growth curves 
of four diﬀerent groups of mice (4 mice per group) treated with  pyrogallol and ACE The tumor volumes were 
measured for each group and the data are presented as mean ± SD. *, ** indicates significant difference at p<0.05 and 
p<0.01 compare to phosphate buffer saline (PBS).
Figure 3. Effect of Treatment with Pyrogallol and ACE on Body Weight of Tumor bearing Mice Tumor bearing Mice 
were Treated with Different Concentrations of ACE and Pyrogallol. Body weight was measured for 21 days with 
intervals of 3 days. Data are presented as Mean ± SD. *, ** indicates significant difference at p<0.05 and p<0.01 
compare to phosphate buffer saline (PBS).   
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pyrogallol treatments (Table 1). The results clearly show 
that mice can tolerate the doses of ACE and pyrogallol, 
which were tested and these can be considered as safe. 
Similarly natural products isolated from medicinal plants 
reported as biocompatible agents (Peng et al., 2015; Yusuf 
et al., 2018).
International Agency for Research on Cancer 
(IARC) classified H. pylori as type 1 human carcinogen 
(Schistosomes, 1994). H. pylori is an infectious organism 
that causes colon cancer associated with infections (De 
Martel et al., 2012). It is well reported that increased risk 
of colonic neopla¬sia in individuals infected with H. pylori 
is associated with the rise of production of gastrin in the 
system triggered by this bacte¬ria (Georgopoulos et al., 
2006; Sonnenberg and Genta, 2013). It is well known 
that oxidative stress resulting from H. pylori infection 
contributes to carcinogenesis (Butcher et al., 2017). Agent 
which can scavenge H. pylori infection mediated reactive 
oxygen species could halt the carcinogenesis. Previously 
we have shown that pyrogallol restricted the in vitro 
growth of H. pylori (Revathi et al., 2018). The molecular 
mechanism of anti H. pylori efficacy of pyrogallol is 
not clear however it can be suggested that pyrogallol 
can alleviate infection of H. pylori by interfering with 
their cell cycle. In this study, tumor bearing mice treated 
with ACE and pyrogallol and observed for reduction 
in tumor burden. Interestingly, pyrogallol reduces the 
tumour size at each time interval significantly, similar to 
doxorubicin (Figure 3). The molecular mechanism of H. 
pylori infection induced colon tumor remission property 
of pyrogallol is unclear. However, it has been suggested 
that inhibition of H. pylori induced gastric inflammation 
associated with oxidative stress is considered as one of 
the promising approaches to prevent carcinogenesis (Cao 
et al., 2007). This statement is in agreement with our 
results where pyrogallol is an antioxidant (Kang et al., 
2011; Li, 2012) and reported to be an anti tumor agent 
in breast cancer and neuroblastoma model (Nemec et 
al., 2016; Sereia et al., 2019). Our current data suggests 
that anti colon tumor efficacy of pyrogallol could be due 
to scavenging of free radicals produced by H. pylori 
induced inflammation associated carcinogenesis in mice. 
Further Cao et al. reported that canolol, an antioxidant 
prevent the incidence of H. pylori associated gastric 
adenocarcinomas by scavenging oxygen radicals and 
reducing the levels of cyclooxygenase-2 (COX-2), 
inducible nitric oxide synthase (iNOS), and serum 
8-hydroxy-2’-deoxyguanosine (8-OHdG) in gerbils (Cao 
et al., 2008). Further experiment is warranted to delineate 
the antioxidant role of pyrogallol in colon cancer model 
(in vivo). 
As chemotherapeutics elicit significant toxicities in 
patients and reflects on reduction of body weight, in our 
study body weight of tumor bearing mice treated with 
ACE and pyrogallol were measured in comparison with 
control group. Administration of ACE and pyrogallol 
did not decline the body weight of mice compared to 
doxorubicin treated mice. ACE and pyrogallol treatment 
found to be safe, however extensive preclinical toxicity 
studies are required to reach definite conclusion.
In conclusion, pyrogallol is an antioxidant molecule, 
profoundly reported for anti cancer activity. In this study, 
we delineate the in vivo anti colon cancer property of 
pyrogallol. Pyrogallol was found to be better tolerated 
by mice. H. pylori infection induced colon cancer model 
was developed and treated with ACE and pyrogallol. 
Tumor bearing mice treated with pyrogallol significantly 
reduced the tumor size in comparison to doxorubicin 
(positive control). Further tumor bearing mice received 
pyrogallol did not show any signs of toxicity in terms 
of loss of body weight, major organ damage, blood cell 
count and fluctuation of blood biochemical parameters. 
However, the molecular mechanism of in vivo anti colon 
cancer activity of pyrogallol should be studied in detail 
and further extensive preclinical studies is required to 
translate this formulation for future clinical trial.
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